drugset / Trial / NCT03718130
Combination HTNV and PUUV DNA Vaccine
Phase 1
Completed
61 enrolled
U.S. Army Medical Research and Development Command
Ichor Medical Systems Incorporated · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabThe Geneva Foundation · collabUS Army Medical Research Institute of Infectious Diseases · collab
RandomizedSingle-groupOpen-labelPrevention
Summary
To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
Timeline
- Start
- 2019-07-10
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hantaan virus vaccine (HTNV) | Vaccine | 0.6 mg | Intramuscular |
| Subject | Hantaan virus vaccine (HTNV) | Vaccine | 3 mg | Intramuscular |
| Subject | Puumala virus vaccine (PUUV) | Vaccine | 0.6 mg | Intramuscular |
| Subject | Puumala virus vaccine (PUUV) | Vaccine | 3 mg | Intramuscular |